Gilead Sciences Inc. (GILD)
Are Medical Stocks Lagging Gilead Sciences (GILD) This Year?
Here is how Gilead Sciences (GILD) and AngioDynamics (ANGO) have performed compared to their sector so far this year.
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note
The latest trading day saw Gilead Sciences (GILD) settling at $106.67, representing a -0.38% change from its previous close.
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $105.87, denoting a -1.53% change from the preceding trading day.
GILD Stock Down on Report of Cut in HIV Prevention Spending
Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash funding for HIV prevention in the country.
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Gilead Dives As HHS Reportedly Mulls Cutting HIV Prevention Funding
Gilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' topline. The post Gilead Dives As HHS Reportedly Mulls Cutting HIV Prevention Funding appeared first on Investor's Business Daily.
Gilead Sciences Stock Slips on Possible HIV Funding Cut
Pharmaceutical stock Gilead Sciences Inc (NASDAQ:GILD) is down 2.6% at $107.34, after news that domestic HIV prevention is under review by the Trump administration, and the Health and Human Services Department could significantly cut funds.
Gilead Stock Falls on Report Trump Administration Wants to Cut HIV-Prevention Funding
Gilead Sciences is the maker of Biktarvy and Descovy, two drugs used to treat the virus.
GILD Stock Trading Close to Its 52-Week High: Should You Buy or Sell?
Gilead Sciences hits a 52-week high buoyed by investor optimism. We believe there is still room for growth and recommend the stock to investors.
Follow the Leader: 2 Biopharma Stocks Showing Relative Strength in 2025
Despite a correction to begin the year, there are a few pockets of the market that are working.
GILD vs. VRTX: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Gilead Sciences (GILD) or Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the better value opportunity right now?
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
